Condition: Obesity · Sponsor: Kailera
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
This description comes directly from the study's public registry record.
Kailera Therapeutics, Inc. · 781-317-0291 · info-clinicalstudies@kailera.com
Always discuss trial participation with your own doctor first.
| Kailera Clinical Site | Glendale, Arizona, United States | Recruiting |
| Kailera Clinical Site | Phoenix, Arizona, United States | Recruiting |
| Kailera Clinical Site | Little Rock, Arkansas, United States | Recruiting |
| Kailera Clinical Site | Northridge, California, United States | Recruiting |
| Kailera Clinical Site | Oceanside, California, United States | Recruiting |
| Kailera Clinical Site | Hamden, Connecticut, United States | Recruiting |
| Kailera Clinical Site | Stamford, Connecticut, United States | Recruiting |
| Kailera Clinical Site | Orange City, Florida, United States | Recruiting |
| Kailera Clinical Site | Albany, Georgia, United States | Recruiting |
| Kailera Clinical Site | Chicago, Illinois, United States | Recruiting |
| Kailera Clinical Site | Skokie, Illinois, United States | Recruiting |
| Kailera Clinical Site | Newton, Kansas, United States | Recruiting |
+ 41 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07284979